Literature DB >> 23426401

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Emma Kipps1, David S P Tan, Stan B Kaye.   

Abstract

Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer, but also provides a wealth of opportunities for translational research. The accessibility of ascitic fluid and its cellular components make it an excellent source of tumour tissue for the investigation of prognostic and predictive biomarkers, pharmacodynamic markers and for molecular profiling analysis. In this Opinion article, we discuss recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites, particularly in the context of ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23426401      PMCID： PMC4673904          DOI： 10.1038/nrc3432

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  151 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Authors:  Y L Hu; M K Tee; E J Goetzl; N Auersperg; G B Mills; N Ferrara; R B Jaffe
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

3.  Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer.

Authors:  Tonya J Webb; Xiangming Li; Robert L Giuntoli; Pablo H H Lopez; Christoph Heuser; Ronald L Schnaar; Moriya Tsuji; Christian Kurts; Mathias Oelke; Jonathan P Schneck
Journal:  Cancer Res       Date:  2012-05-30       Impact factor: 12.701

4.  Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells.

Authors:  Ling-Zhi Liu; Xiao-Wen Hu; Chang Xia; Jie He; Qiong Zhou; Xianglin Shi; Jing Fang; Bing-Hua Jiang
Journal:  Free Radic Biol Med       Date:  2006-08-07       Impact factor: 7.376

5.  A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

Authors:  Nicoletta Colombo; Giorgia Mangili; Serafina Mammoliti; Mårten Kalling; Bengt Tholander; Lars Sternas; Giliane Buzenet; Donald Chamberlain
Journal:  Gynecol Oncol       Date:  2011-11-21       Impact factor: 5.482

6.  [Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter].

Authors:  R Saiz-Mendiguren; M Gómez-Ayechu; J J Noguera; A García-Lallana; C Marginet; D Cano; A Benito
Journal:  Radiologia       Date:  2010-09-21

7.  Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients.

Authors:  Trevor G Shepherd; Brigitte L Thériault; Elizabeth J Campbell; Mark W Nachtigal
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

8.  Role of endothelin-1 in neovascularization of ovarian carcinoma.

Authors:  D Salani; V Di Castro; M R Nicotra; L Rosanò; R Tecce; A Venuti; P G Natali; A Bagnato
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

9.  Secretion of vascular endothelial growth factor in ovarian cancer.

Authors:  A D Santin; P L Hermonat; A Ravaggi; M J Cannon; S Pecorelli; G P Parham
Journal:  Eur J Gynaecol Oncol       Date:  1999       Impact factor: 0.196

10.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482
View more
  227 in total

1.  Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients.

Authors:  Jessica Vazquez; Melina Chavarria; Gladys E Lopez; Mildred A Felder; Arvinder Kapur; Antonio Romo Chavez; Nathan Karst; Lisa Barroilhet; Manish S Patankar; Aleksandar K Stanic
Journal:  Am J Reprod Immunol       Date:  2020-06-30       Impact factor: 3.886

2.  A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer.

Authors:  Jing Zhao; Xinxiao Chen; Aimu Zhang; Feng Xu; Meilong Hu; Congying Xie; Shengliu Xue
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

3.  High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.

Authors:  Frank Antony; Cecilia Deantonio; Diego Cotella; Maria Felicia Soluri; Olga Tarasiuk; Francesco Raspagliesi; Fulvio Adorni; Silvano Piazza; Yari Ciani; Claudio Santoro; Paolo Macor; Delia Mezzanzanica; Daniele Sblattero
Journal:  Oncoimmunology       Date:  2019-06-04       Impact factor: 8.110

4.  M-Trap: Exosome-Based Capture of Tumor Cells as a New Technology in Peritoneal Metastasis.

Authors:  Alexandre de la Fuente; Lorena Alonso-Alconada; Clotilde Costa; Juan Cueva; Tomas Garcia-Caballero; Rafael Lopez-Lopez; Miguel Abal
Journal:  J Natl Cancer Inst       Date:  2015-07-06       Impact factor: 13.506

5.  Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors:  Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal:  J Control Release       Date:  2019-05-17       Impact factor: 9.776

6.  Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.

Authors:  Chase L Johnson; Daniel S Green; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

7.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

8.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

9.  Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites.

Authors:  Tongtong Kan; Wei Wang; Philip P Ip; Shengtao Zhou; Alice S Wong; Xin Wang; Mengsu Yang
Journal:  Oncogene       Date:  2020-04-13       Impact factor: 9.867

10.  Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.

Authors:  Shreya Raghavan; Maria R Ward; Katelyn R Rowley; Rachel M Wold; Shuichi Takayama; Ronald J Buckanovich; Geeta Mehta
Journal:  Gynecol Oncol       Date:  2015-04-22       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.